Deliver Your News to the World

New DNA test will improve tracking of Salmonella food-poisoning outbreaks

The test may rapidly and sensitively distinguish subtypes of Salmonella, reports The Journal of Molecular Diagnostics

Philadelphia – WEBWIRE

Researchers report the development of a sensitive and specific assay to detect different serotypes of Salmonella, paving the way for rapid serotyping directly from specimens. This improvement upon current testing methods can play a critical role in quickly tracing the origin of the infection. The report appears in The Journal of Molecular Diagnostics, published by Elsevier.

Recent data from the Centers for Disease Control and Prevention (CDC) indicate that food poisoning caused by Salmonella bacteria leads to 1.35 million infections, 26,500 hospitalizations, and 420 deaths in the United States per year. During an outbreak, the speed and simplicity of a test to detect specific types of bacteria are important for public health investigators to track down the source.

Salmonella in a clinical or food sample may be present in very small amounts and thus requires very sensitive methods to detect them. Multiple cross-displacement amplification (MCDA) is a method that can detect very small amounts of DNA rapidly and is also performed at a single constant temperature, in contrast to the cycling of temperatures required in other methods such as PCR. This makes it a good fit for a simple, rapid, and sensitive bacterial detection test. Although an MCDA test for any Salmonella already exists, it does not distinguish between different serotypes,” explained Professor Ruiting Lan, PhD, of the School of Biotechnology and Biomolecular Sciences at the University of New South Wales, Sydney, NSW, Australia.

The investigators developed an MCDA assay for each of the seven serovar (subtype)-specific targets of Salmonella. All of these assays accurately detect as few as 10 copies of DNA and can produce results in approximately eight minutes. Importantly, these assays do not require specialized detection equipment, simplifying any future application in clinical or industrial settings. By combining these seven serovar-specific assays with the existing species assay, Salmonella detection can be simplified and accelerated.

“The assays developed in this study are unique because the gene markers used were selected based on analyzing thousands of genomes. Thus, these markers future proof Salmonella serotyping in the era of culture-independent diagnostic testing,” commented Professor Lan.

Traditional methods to distinguish Salmonella serotypes involve growing the bacteria from samples and then testing them to assign them to a serovar. The MCDA test is faster because it does not require first growing the bacteria in culture. Rather, it can detect very small amounts of Salmonella DNA.

Although there are hundreds of Salmonella serovars, the authors chose the five most commonly occurring in Australia, which cause more than 85 percent of Salmonella infections in that country. However, at least two of these serovars are also the top Salmonella serovars throughout the world, therefore the researchers believe the results are applicable to other geographic regions.

Salmonella bacteria typically live in animal and human intestines and are shed through feces. Humans may become infected by ingesting contaminated water or food such as raw or undercooked meat, poultry, eggs, or egg products. Possible signs and symptoms of Salmonella poisoning include nausea, vomiting, abdominal cramps, diarrhea, fever, and headache.


Notes for editors
The article is “Highly Sensitive and Specific Detection and Serotyping of Five Prevalent Salmonella Serovars by Multiple-Cross Displacement Amplification,” by Xiaomei Zhang, Michael Payne, Qinning Wang, Vitali Sintchenko, and Ruiting Lan ( It will appear in The Journal of Molecular Diagnostics, volume 22, issue 5 (May 2020) published by Elsevier.

About The Journal of Molecular Diagnostics
The Journal of Molecular Diagnostics, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirectScopusSciValClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray’s Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

( Press Release Image: )


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.